Technologies for target identification, deconvolution, and selectivity profiling

Advances in drug discovery demand faster, deeper insight into target identification, deconvolution, and selectivity profiling. Traditional methods are often slow, costly, and limited in throughput, restricting their use to only a few candidate compounds and delaying confident decision‑making early in R&D.

Discover how next‑generation, automation‑ready chemoproteomic and mass‑spectrometry‑based technologies enable scalable, label‑free analysis with proteome‑wide readouts. Plus, learn how these approaches allow scientists to analyze hundreds of compounds efficiently, improve target confidence, and accelerate research progression.